A multicenter randomized study evaluating the efficacy and safety of HMG-CoA reductase inhibitors (statins) in dyslipidemic patients with nephrosclerosis.
Not Applicable
- Conditions
- ephrosclerosis
- Registration Number
- JPRN-UMIN000007130
- Lead Sponsor
- Omihachiman Community Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 77
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients who are treated with statins 2. Patients who are planned to start or change medication for renal disease 3. Severe hypertensive patients (SBP>=150mmHg or DBP >=90mmHg) 4. Severe hepatic dysfunction 5. Abnormal values of serum creatinine caused by any disease except renal disease 6. BMI>25(kg/m2) 7. Patients with thyroid dysfunction 8. History of acute myocardial infarction or stroke during three months prior to the registration 9. Pregnant, breast feeding, or could be pregnant 10. Patients who do not accept informed consent 11. Patients judged as being inappropriate for this study by investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method An absolute change of estimated glomerular filtration rate
- Secondary Outcome Measures
Name Time Method 1. An absolute change of renal function -urinary albumin or protein, serum creatinine, urinary beta 2 microglobulin(BMG), urinary N-acetyl-beta-D-glucosaminidase(NAG) 2. An absolute change of serum lipids -TC, LDL-C, TG, HDL-C, non HDL-C, apolipoprotein(Apo A-I, Apo A-II, ApoB)